Patients with nonischemic systolic heart failure are at an increased risk of sudden cardiac death, but more discriminating tools are needed to identify those patients likely to benefit from implantable cardioverter-defibrillator (ICD) implantation. Whether right ventricular (RV) ejection fraction (RVEF) can identify patients with nonischemic systolic heart failure more likely to benefit from ICD implantation is not yet known.
P
atients with nonischemic systolic heart failure have an increased mortality rate, primarily because of increased risk of sudden cardiac death (SCD) and progressive contractile dysfunction. 1 Implantation of a primary prophylactic implantable cardioverter-defibrillator (ICD) is recommended to patients with nonischemic systolic heart failure and left ventricular (LV) ejection fraction (LVEF) ≤35%. 2, 3 The DANISH trial (Danish Study to Assess the Efficacy of ICDs in Patients With Nonischemic Systolic Heart Failure on Mortality) did not demonstrate an overall reduction in all-cause mortality when patients with symptomatic nonischemic systolic heart failure were treated with an ICD. 4 Thus, there is a need for better identification of patients with nonischemic systolic heart failure who are likely to benefit from defibrillator implantation.
The interaction between the right ventricle (RV) and the LV in patients with nonischemic systolic heart failure is not fully understood. In patients with mildly to moderately reduced LVEF, reduced RV ejection fraction (RVEF) has been shown to be a strong predictor of arrhythmic events. 5 In addition, RV dysfunction is an independent prognostic marker of heart failure related death, heart failure hospitalization, and transplantfree survival in patients with nonischemic systolic heart failure. 6, 7 It is not known, however, whether structural and functional parameters of the RV can modify the effect of ICD implantation in patients with LV systolic heart failure.
Cardiovascular magnetic resonance (CMR) is considered the gold standard for RV assessment, and RV volumes and function can be measured noninvasively with high accuracy and reproducibility. 8, 9 The purpose of this post hoc analysis of the DANISH trial was to investigate the association of RVEF with all-cause mortality, cardiovascular death, and SCD and whether patients with nonischemic LV systolic heart failure who also had reduced RVEF were more likely to benefit from ICD implantation.
METHODS

Patients
The DANISH CMR substudy was conducted between February 7, 2008 , and June 27, 2014, as part of the DANISH trial. 4 Patients without an event were right-censored at the end of follow-up June 30, 2016. Only patients randomized at Rigshospitalet were included in the substudy. The detailed design of the DANISH trial has been reported previously. 10 In brief, DANISH was a randomized controlled trial of the effect of ICD implantation on all-cause mortality in patients with nonischemic systolic heart failure. 4 Nonischemic pathogenesis was determined by invasive coronary angiography (96% of patients), computed tomographic angiography, or nuclear myocardial perfusion imaging study. Patients with LVEF ≤35% on echocardiography and increased levels (>200 pg/mL) of NT-proBNP (N-terminal pro-brain natriuretic peptide) could be randomized to ICD or control.
Participants in the substudy underwent a CMR scan after randomization but before potential ICD or cardiac resynchronization therapy (CRT) implantation. Exclusion criteria for the CMR substudy included severe renal impairment (estimated glomerular filtration rate <30 mL/[min·1.73 m2]), severe claustrophobia, or implanted metallic foreign bodies (eg, aneurysm clips or pacemaker electrodes). In total, 252 patients were included and completed a CMR scan. However, 13 patients were subsequently excluded because of uninterpretable images of the RV, with 239 patients needing further analysis. All patients gave informed consent to participate.
The data will not be made available to other researchers for purposes of reproducing the results or replicating the procedure because of constraints related to human subjects research. Analytical methods will be made available on request.
Ethics
The study was performed according to the principles of the Declaration of Helsinki. Patients were enrolled only after providing informed consent. The study was approved by the regional scientific ethics committee for the capital region (H-D-2007-0101) and the Danish Data Protection Agency. In addition, the trial is registered at http://www.clinicaltrials. gov. Unique identifier: NCT00542945.
Cardiac Magnetic Resonance Protocol
CMR scans were performed on a 1.5-T scanner (Siemens Espree, Erlangen, Germany). Short-axis cine images were acquired with a steady-state free-precession pulse sequence in long-axis planes and contiguous 8 mm short-axis slices from the mitral annulus to the apex without any interpolation. Late gadolinium enhancement (LGE) images were
WHAT IS KNOWN?
• Dysfunction of the right ventricle is a well-recognized predictor of all-cause mortality in patients with nonischemic left ventricular systolic heart failure.
• Implantable cardioverter-defibrillator implantation in patients with nonischemic systolic heart failure is debatable after the DANISH trial (Danish Study to Assess the Efficacy of ICDs in Patients With Nonischemic Systolic Heart Failure on Mortality), and whether right ventricular ejection fraction can identify patients with nonischemic systolic heart failure more likely to benefit from implantable cardioverter-defibrillator implantation is not yet known.
WHAT THE STUDY ADDS?
• The presence of combined right ventricular dysfunction and left ventricular dysfunction is associated with greater benefit from implantable cardioverter-defibrillator therapy.
performed using a standard inversion-recovery gradient echo pulse sequence 10 minutes after intravenous injection of 0.1 mmol/kg of gadolinium. To exclude artifacts, long-and short-axis planes were performed similar to cine images. In addition, short-axis imaging was performed in 2 different phase-encoding directions, and cross-sectional long-axis views of specific regions were acquired to verify LGE. Inversion time was 250 to 350 ms (manually adjusted to optimally null the myocardium).
Data Analysis
One experienced investigator blinded to baseline characteristics and randomization performed the CMR analysis of LV and RV volume and function. For the RV, endocardial borders were traced in end-diastole and end-systole; the papillary muscles were incorporated as part of the myocardium. For the LV, endocardial borders were traced in end-diastole and end-systole, and epicardial borders were traced in enddiastole. Papillary muscles were excluded from the blood pool. End-diastole was identified using R wave triggered first shot and end-systole as the smallest cavity dimension according to the blood pool area. All analyses were performed on the short-axis cine images with software CMR tools (Cardiovascular Imaging Solutions, London, United Kingdom). All measurements were indexed to body surface area (BSA) using the Mosteller formula. 11 RV dysfunction was determined as RVEF ≤45%, similarly defined in previous studies. 5, 6 Myocardial LGE was quantified by the full with/half maximum method using the software CVI 42 (5.5.1; Circle Cardiovascular Imaging, Calgary, AB, Canada). 12 LGE was considered present if visible in 2 phase-encoding directions and 2 orthogonal planes. Patients that only presented with insertion point fibrosis were not grouped as having LGE, which is the clinical practice at both Rigshospitalet and Royal Brompton Hospital.
Follow-Up and End Points
In accordance with the main DANISH trial, the predefined primary end point was death from any cause, and the secondary end points were cardiovascular death and SCD. All were adjudicated according to previously reported criteria by a clinical end point committee. 4 Cardiovascular deaths were subclassified as sudden or nonsudden. SCD was defined as death occurring unexpectedly in a previously stable patient, death occurring within an hour of onset or worsening of symptoms, or unwitnessed death, in which patients were last seen alive <72 hours before death with no sign of life-threatening disease or symptoms, and when circumstances suggested sudden death (such as when a patient was found in bed).
Statistics
Baseline characteristics of the groups according to RV dysfunction were compared using χ 2 and Wilcoxon tests. Presented numbers are given as the median number and the interquartile range. All variables not normally distributed were log-transformed. Outcomes were analyzed with the use of time-to-event methods. All analyses were performed in the intention-to-treat population. Kaplan-Meier curves and cumulative incidence curves were calculated for total mortality, cardiovascular death, and SCD. An interaction was defined, where the treatment effect differed between levels of RV function. Model assumptions on interactions and linearity were assessed and met, whereas the proportionalhazard assumption was assessed and met with Martingale residuals. In all adjusted analysis, the CMR determined LVEF variable has been used. LGE could not be analyzed in all patients and, therefore, not included in the multivariable models. However, if included, this did not change the point estimates, and the interaction models remained highly significant. Two-sided P values of ≤0.05 were considered statistically significant. All analyses were performed with SAS software version 9.4 (SAS Institute, Cary, NC) and R software version 3.3.1 (R Project for Statistical Computing).
RESULTS
A total of 239 patients underwent a CMR scan and had analyzable images of the RV. The inclusion is described in the flowchart, Figure 1 . Patients were 61 years old on average, whereas 73% were men. In all, 111 (46%) patients were randomized to an ICD, and 58 of these received a CRT-defibrillator. In the control group, 53 of the 128 patients received a CRT-pacemaker. The median follow-up time was 5.3 years. Baseline characteristics of patients according to RV dysfunction are presented in Table 1 . A total of 75 patients (31%) had RV dysfunction. In comparison with patients without RV dysfunction, patients with RV dysfunction were in a higher New York Heart Association (NYHA) class, more often having permanent atrial fibrillation, longer duration of heart failure, and a higher concentration of NT-proBNP. Median RVEF for the population was 51% (41%-61%), Figure I in the Data Supplement. Additional CMR variables according to RV dysfunction are shown in Table 2 . Differences between the patients with and without analyzable RV images are presented in the Table I in the Data Supplement, and differences between patients included in the substudy and the remaining DANISH population are presented in the Table II in the Data Supplement.
RV Function and Mortality
The primary outcome, death from any cause, occurred in 55 (23%) patients, cardiovascular death occurred in 39 (16%) patients, and 20 (8%) patients died from SCD. Of patients with RV dysfunction, 27 (36%) died from any cause, 19 (25%) patients died from a cardiovascular cause, and 7 (9%) died from SCD. The annual mortality rate for the overall population was 4.52 (95% CI, 4.37-5.89) deaths per 100 person-years, 3.17 (95% CI, 2.19-4.59) deaths per 100 person-years for patients without RV dysfunction, and 8.11 (95% CI, 5.56-11.82) death per 100 person-years for patients with RV dysfunction.
For every absolute 10% decrease in RVEF, the relative hazard of all-cause death increased by 39.6% (95% CI, 16.4-67.4), P=0.0003. In a univariable model, the hazards ratio (HR) for all-cause death according to the presence of RV dysfunction was 2.80 (CI 1.64 -4.77), P=0.0002. Both RVEF (10% decrease) and RV dysfunction remained independent predictors of allcause mortality after adjusting for LVEF, age, sex, NTproBNP, CRT, ICD, NYHA class, and atrial fibrillation, HR 1.34 (95% CI, 1.05-1.70), P=0.02 and HR 2.29 (95% CI, 1.20-4.37), P=0.01. Adding RV dysfunction to the full model improved the C statistic from 0.658 to 0.670, and the net reclassification index was 0.23. Regression analysis with RVEF and RV dysfunction as predictors of all-cause death, cardiovascular death, and SCD are presented in Table 3 . Full information of all covariates are presented in the Table III in the Data  Supplement. In a multivariable model NT-proBNP, atrial fibrillation, duration of heart failure, and lower LVEF were significantly associated with the presence of RV dysfunction, Table IV in the Data Supplement.
RV Function and Effect of ICD on AllCause Mortality
There was a significantly different effect of ICD implantation on all-cause mortality depending on RV function, regardless of whether RV function was assessed by RVEF as a continuous variable (P for interaction=0.001) or as RV dysfunction (P for interaction=0.01). The interaction remained significant after controlling for age, sex, duration of heart failure, NTproBNP, NYHA class, CRT, LVEF, randomization to ICD or control, and atrial fibrillation for RVEF (P for interaction=0.002 and for RV dysfunction (P for interaction=0.01). For patients without RV dysfunction, ICD did not improve all-cause mortality HR, 1.83; 95% CI, 0.85-3.92; P=0.12, but for patients with RV dysfunction, an ICD significantly reduced all-cause mortality, HR, 0.41; 95% CI, 0.17-0.97; P=0.042. The Kaplan-Meier curves for event-free survival according to RV dysfunction and treatment strategy (ICD or control) are presented in Figure 2 . The Kaplan-Meier curves for all-cause mortality according to RV function regardless of treatment strategy are presented in the Figure II in the Data Supplement. Effect of ICD on all-cause mortality, cardiovascular death, and SCD are presented in Table 4 .
There was no interaction between CRT and RV dysfunction (P for interaction=0.47) on all-cause mortality. Kaplan-Meier curves for event-free survival according to RV dysfunction and CRT-defibrillator versus CRTpacemaker are presented in the Figure III 
RV Function and Effect of ICD on Cardiovascular Death
There was a significant interaction related to the risk of cardiovascular death depending on treatment with ICD or control and RVEF as a continuous variable (P for interaction=0.0007) and for RV dysfunction (P for interaction=0.01). The interaction remained significant after controlling for age, sex, duration of heart failure, NT-proBNP, NYHA class, CRT, LVEF, randomization to ICD or control, and atrial fibrillation for RVEF (P for interaction=0.002), and for RV dysfunction (P for interaction=0.01). For patients without RV dysfunction, an ICD did not affect the risk of cardiovascular death HR, 
RV Function and Effect of ICD on SCD
Although the number of events was small, there was also a significant interaction on SCD between treatment with ICD or control and RVEF as a continuous variable (P for interaction=0.04), which was maintained after adjusting for age, sex, NT-proBNP, NYHA class, Body surface area is calculated by the Mosteller formula. ACE indicates angiotensin-converting enzyme; ARB, angiotensin-receptor blocker; BMI, body mass index; CMR, cardiac magnetic resonance; CRT, cardiac resynchronization therapy; eGFR, estimated glomerular filtration rate; ICD, implantable cardioverter-defibrillator; IQR, interquartile range; MRA, mineralocorticoid-receptor antagonist; NT-proBNP, N-terminal pro-brain natriuretic peptide; NYHA, New York Heart Association; and RVEF, right ventricular ejection fraction.
*The body mass index is the weight in kilograms divided by the square of the height in meters.
CRT, LVEF, randomization to ICD or control, and atrial fibrillation (P for interaction=0.04). The interaction for RV dysfunction was nonsignificant (P=0.07). For patients without RV dysfunction, an ICD did not affect the risk of SCD HR, 1.15; 95% CI, 0.38-3.50; P=0.80. For patients with RV dysfunction, there was a borderline effect of ICD on the risk of SCD HR, 0.14; 95% CI, 0.02-1.28; P=0.08. The cumulative incidence curves for SCD are presented in Figure 3B .
DISCUSSION
In this post hoc analysis of patients with nonischemic LV systolic heart failure randomized to ICD implantation or control in the DANISH trial, RV function measured on CMR was associated with benefit from ICD implantation on risk of all-cause mortality and SCD. Patients with RV dysfunction had more than a 2-fold increased risk of all-cause death compared with patients without dysfunction of RV. In addition, in the group of patients with RV dysfunction, ICD implantation reduced the risk of all-cause death by 55%, whereas there was no effect of ICD implantation in patients without dysfunction of the RV. An ICD seemed to greatly reduce the risk of SCD in patients with reduced RV dysfunction. To our knowledge, these are the first data to show that ICD implantation might be more effective in patients with nonischemic heart failure who also have biventricular heart failure. Patients with RV dysfunction appear worse in multiple baseline parameters and seem to be a sicker population. However, the baseline characteristics differ between the groups are not known predictors of the need for an ICD. Also, RV function remained an independent predictor of all-cause death after adjustment for all these differences and still affecting the need for an ICD, leading to independent information in the process of selecting patients for ICD implantation.
The DANISH study found that ICD implantation for patients with nonischemic systolic heart failure did not improve overall survival. 4 Accurate risk stratification of patients with nonischemic systolic heart failure is, therefore, highly important. Identification of patients who are most likely to benefit from ICD therapy will improve patient care and health outcomes in a costeffective manner.
Our study suggests that RVEF assessment might be an important part of risk stratification of ICD candidates. RV parameters are difficult to obtain by echocardiography because of their asymmetrical shape, highly trabeculated endocardial surface, and a bellows-like contraction pattern. 13 However, CMR has a great reproducibility of RV parameters and yields a more accurate measure of the RV.
14 The present analysis underscores the role of CMR in risk stratification of patients with nonischemic systolic heart failure and suggests that the assessment of RVEF may further enhance the utility of CMR in these patients. There is currently no international consensus on the threshold The multivariable models were adjusted for LVEF, age, sex, NT-proBNP, ICD implantation, CRT treatment, NYHA class, and atrial fibrillation. RV dysfunction was defined as RVEF ≤45%. CRT indicates cardiac resynchronization therapy; ICD, implantable cardioverterdefibrillator; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-brain natriuretic peptide; NYHA, New York Heart Association; RV, right ventricular; RVEF, right ventricular ejection fraction; and SCD, sudden cardiac death. of CMR-derived RVEF for RV dysfunction. Our definition of RV dysfunction is based on the cutoff value previously shown to identify those at higher risk of arrhythmic events among patients with nonischemic LV systolic heart failure. 5, 6 However, we found the same significant interaction when we used continuous values for RVEF.
The mechanism for the increased risk of ventricular arrhythmia in patients with RV dysfunction in addition to nonischemic LV dysfunction is not well understood. The interaction between LV and RV dysfunction is complex and includes ventricular interdependence with septal dysfunction, neurohormonal interaction, and reduced perfusion of the RV secondary to decreased cardiac output, which may lead to both reentrant and focal ventricular arrhythmias. 13, 15 Also, it is possible that a diseased RV in itself is more arrhythmogenic, or the presence of biventricular failure in nonischemic cardio- For patients without RV dysfunction, the survival curves are not significantly different according to treatment with either ICD or control (log-rank P=0.18) -but for patients with RV dysfunction, the survival curves differ significantly according to treatment (log-rank P=0.04). RV dysfunction is defined as RV ejection fraction (RVEF) ≤45%. RV dysfunction was defined as RVEF ≤45%. The multivariable models were adjusted for LVEF, age, sex, NT-proBNP, CRT treatment, NYHA class, and atrial fibrillation. CRT indicates cardiac resynchronization therapy; ICD, implantable cardioverter-defibrillator; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-brain natriuretic peptide; NYHA, New York Heart Association; RV, right ventricular; RVEF, right ventricular ejection fraction; and SCD, sudden cardiac death. myopathy may be an indicator of a more generalized cardiomyopathy, with higher risk of malignant arrhythmias such as arrhythmogenic RV cardiomyopathy with LV involvement.
Limitations
Although assessment of RVEF as a predictor of outcomes was preplanned in the DANISH CMR protocol, the interaction with ICD implantation is a post hoc analysis. Patients participating in the magnetic resonance imaging substudy are slightly different from the rest of the DANISH population, primarily because of contraindications of CMR scanning. Only patients from 1 center participated in this substudy, making the sample size small, which influences reproducibility and the association between RV function and SCD. More detailed arrhythmic data was not available. Average LVEF measured by CMR after study inclusion was higher than the LVEF from echocardiography reported at baseline. This likely reflects differences between the imaging methods and the time lapse between qualifying echocardiography (which could be six months old at the time of inclusion) and the CMR study.
Conclusions
RVEF is an independent predictor of all-cause mortality in patients with nonischemic LV systolic heart failure. In this post hoc analysis of the DANISH trial, the presence of combined RV dysfunction and LV dysfunction is associated with greater benefit from ICD therapy. Cumulative incidence curves of (A) cardiovascular death and (B) SCD according to RV dysfunction and treatment to either ICD or control. Implantation of an ICD did not affect the risk of cardiovascular death was for patients without RV dysfunction (log-rank P=0.16), but for patients with RV dysfunction, the risk was significantly different (log-rank P=0.02). The risk of SCD was not significantly different according to treatment with either ICD or control (P=0.80), and for patients with RV dysfunction, the risk of SCD was borderline significantly according to treatment (P=0.08). RV dysfunction is defined as RV ejection fraction (RVEF) ≤45%.
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